Zenith Health Care Ltd
Incorporated in 1993, Zenith Healthcare Ltd is engaged in trading and manufacturing of pharmaceutical products.
- Market Cap ₹ 30.8 Cr.
- Current Price ₹ 5.74
- High / Low ₹ 6.87 / 3.61
- Stock P/E 514
- Book Value ₹ 1.41
- Dividend Yield 0.00 %
- ROCE 3.98 %
- ROE 2.75 %
- Face Value ₹ 1.00
Pros
- Company is almost debt free.
- Company's working capital requirements have reduced from 75.6 days to 59.0 days
Cons
- Stock is trading at 4.00 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
- The company has delivered a poor sales growth of 8.04% over past five years.
- Promoter holding is low: 28.7%
- Company has a low return on equity of 2.75% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
4.01 | 3.27 | 3.64 | 3.46 | 4.79 | 9.51 | 9.83 | 11.98 | 13.74 | 22.36 | 13.13 | 14.47 | 12.56 | |
4.15 | 3.54 | 3.68 | 3.69 | 4.73 | 8.95 | 9.63 | 11.43 | 13.38 | 21.91 | 13.10 | 14.24 | 12.48 | |
Operating Profit | -0.14 | -0.27 | -0.04 | -0.23 | 0.06 | 0.56 | 0.20 | 0.55 | 0.36 | 0.45 | 0.03 | 0.23 | 0.08 |
OPM % | -3.49% | -8.26% | -1.10% | -6.65% | 1.25% | 5.89% | 2.03% | 4.59% | 2.62% | 2.01% | 0.23% | 1.59% | 0.64% |
0.32 | 0.10 | 0.05 | 0.12 | 0.08 | 0.13 | 0.21 | 0.30 | 0.46 | 0.52 | 0.38 | 0.27 | 0.34 | |
Interest | 0.00 | 0.00 | 0.01 | 0.01 | 0.01 | 0.01 | 0.00 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
Depreciation | 0.17 | 0.24 | 0.35 | 0.35 | 0.30 | 0.28 | 0.25 | 0.25 | 0.25 | 0.36 | 0.28 | 0.21 | 0.18 |
Profit before tax | 0.01 | -0.41 | -0.35 | -0.47 | -0.17 | 0.40 | 0.16 | 0.59 | 0.56 | 0.60 | 0.12 | 0.28 | 0.23 |
Tax % | 100.00% | -31.71% | -31.43% | -36.17% | -11.76% | 32.50% | 18.75% | 3.39% | 19.64% | 48.33% | 33.33% | 25.00% | |
0.01 | -0.27 | -0.24 | -0.31 | -0.15 | 0.27 | 0.14 | 0.57 | 0.44 | 0.31 | 0.08 | 0.20 | 0.06 | |
EPS in Rs | 0.00 | -0.05 | -0.04 | -0.06 | -0.03 | 0.05 | 0.03 | 0.11 | 0.08 | 0.06 | 0.01 | 0.04 | 0.02 |
Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Compounded Sales Growth | |
---|---|
10 Years: | 16% |
5 Years: | 8% |
3 Years: | 2% |
TTM: | -3% |
Compounded Profit Growth | |
---|---|
10 Years: | 11% |
5 Years: | 7% |
3 Years: | -23% |
TTM: | -77% |
Stock Price CAGR | |
---|---|
10 Years: | 23% |
5 Years: | 36% |
3 Years: | -8% |
1 Year: | 18% |
Return on Equity | |
---|---|
10 Years: | 2% |
5 Years: | 5% |
3 Years: | 3% |
Last Year: | 3% |
Balance Sheet
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 5.37 | 5.37 | 5.37 | 5.37 | 5.37 | 5.37 | 5.37 | 5.37 | 5.37 | 5.37 | 5.37 | 5.37 | 5.37 |
Reserves | 0.95 | 0.68 | 0.48 | 0.17 | 0.02 | 0.29 | 0.43 | 1.03 | 1.47 | 1.78 | 1.86 | 1.96 | 2.21 |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
0.80 | 0.78 | 0.60 | 1.04 | 0.74 | 1.43 | 1.14 | 2.14 | 1.92 | 4.52 | 2.02 | 2.42 | 2.94 | |
Total Liabilities | 7.12 | 6.83 | 6.45 | 6.58 | 6.13 | 7.09 | 6.96 | 8.54 | 8.76 | 11.67 | 9.25 | 9.75 | 10.52 |
1.62 | 1.37 | 2.17 | 1.93 | 1.75 | 1.81 | 1.62 | 1.70 | 1.80 | 1.75 | 1.50 | 1.40 | 1.67 | |
CWIP | 0.00 | 0.79 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.17 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 0.20 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
5.30 | 4.67 | 4.28 | 4.65 | 4.38 | 5.28 | 5.34 | 6.67 | 6.96 | 9.92 | 7.75 | 8.35 | 8.85 | |
Total Assets | 7.12 | 6.83 | 6.45 | 6.58 | 6.13 | 7.09 | 6.96 | 8.54 | 8.76 | 11.67 | 9.25 | 9.75 | 10.52 |
Cash Flows
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
0.01 | -0.07 | 0.19 | 0.23 | 0.23 | 0.00 | -0.06 | 1.95 | -1.47 | 1.32 | -0.92 | 1.74 | |
-0.07 | -0.44 | -0.14 | 0.01 | -0.12 | 0.00 | -0.05 | -0.50 | -0.19 | -0.23 | -0.03 | -0.11 | |
-0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | -0.02 | 0.00 | 0.00 | 0.00 | 0.00 | |
Net Cash Flow | -0.07 | -0.51 | 0.05 | 0.24 | 0.11 | 0.00 | -0.09 | 1.44 | -1.65 | 1.09 | -0.95 | 1.63 |
Ratios
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 212.08 | 218.78 | 183.50 | 132.92 | 84.58 | 54.88 | 33.79 | 31.08 | 44.89 | 53.05 | 64.22 | 50.70 |
Inventory Days | 146.30 | 192.90 | 170.89 | 297.41 | 179.91 | 102.66 | 125.86 | 99.18 | 145.11 | 104.78 | 147.45 | 91.25 |
Days Payable | 105.58 | 132.38 | 86.27 | 177.67 | 78.95 | 82.53 | 47.61 | 84.31 | 71.22 | 37.63 | 51.11 | 33.64 |
Cash Conversion Cycle | 252.81 | 279.29 | 268.12 | 252.65 | 185.54 | 75.01 | 112.04 | 45.95 | 118.78 | 120.21 | 160.55 | 108.31 |
Working Capital Days | 258.50 | 296.91 | 246.68 | 208.87 | 136.40 | 82.13 | 96.91 | 48.14 | 98.02 | 50.93 | 116.76 | 59.03 |
ROCE % | -3.01% | -6.79% | -5.71% | -8.08% | -2.93% | 7.42% | 2.79% | 9.82% | 8.61% | 8.72% | 1.81% | 3.98% |
Documents
Announcements
- Submission Of Unaudited Financial Results For The Quarter And Half Year Ended On 30Th September, 2023 Along With Limited Review Report. 24 Oct
-
Board Meeting Outcome for Outcome Of Board Meeting
24 Oct - Board approved financial results and related party transactions.
-
Board Meeting Intimation for Intimation Of Board Meeting To Be Held On Thursday, October 24, 2024
17 Oct - Board meeting scheduled for October 24, 2024.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
15 Oct - Submission of Declaration of RTA under Regulation 74(5) of Depositories and Participants Regulation 2018.
- Closure of Trading Window 27 Sep
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Product Profile:[1]
a) Pharmaceutical Pills: Alprazolam & Propranolol HCL Tablets, Pantoprazole Sodium Levosulpiride Capsules, Vicadol, Mdzime
b) Pharmaceutical Syrup And Protein Powder: Azithromycin Dihydrate Suspension, Cofzen Syrup, Domperidone Suspension, Zenoset Syrup, Valprex Syrup
c) Oral Rehydration Salt: Albendazole Oral Suspension, Erythromycin Oral Suspension
d) Sertraline Tablets: Alprazolam & Sertraline Tablets
e) Antipsychotic: Loxapine Drops
f) Omeprazole Capsules